消息公布后，礼来美股盘前一度涨逾1.5%，最终收涨0.62%。由于减肥药的高需求，截至收盘，今年迄今礼来公司股价已累涨近56%。US pharmaceutical giant Eli Lilly and Co. announced that Lucas Montarce, a senior financial expert within the company, has been appointed as the Chief Financial Officer, and the appointment is effective immediately. This personnel change comes at a critical moment as Eli Lilly is investing billions of dollars to expand production to meet the increasing demand for its diabetes and weight loss drugs (such as Mounjaro and Zepbound). Despite FDA approval, Eli Lilly still faces supply shortages.
On Monday, September 9th, US pharmaceutical company $Eli Lilly and Co (LLY.US)$ announced the appointment of internal senior finance expert Lucas Montarce as the new Chief Financial Officer, effective immediately. This appointment was made several months after former CFO Anat Ashkenazi left to join Google's parent company, Alphabet.
This executive change at Eli Lilly comes at a crucial time as the company is investing billions of dollars to expand its production capacity in response to the surging demand for its diabetes and weight loss drugs (such as Mounjaro and Zepbound).
After the announcement, Eli Lilly and Co. rose over 1.5% in pre-market trading and ultimately closed up 0.62%. Due to high demand for weight loss drugs, the company's stock price has risen nearly 56% year-to-date as of the closing. Some analysts predict that the global weight loss drug market could exceed $150 billion by the early 2030s.
Since joining Eli Lilly in 2001, Lucas Montarce has had extensive financial management experience. He has served as the finance director in Eli Lilly's research laboratories and international division, and earlier this year, he held the position of President and General Manager for Eli Lilly's Spain, Portugal, and Greece region. In his new role, Montarce will serve as both Chief Financial Officer and Executive Vice President, with an annual base salary of $1 million and eligibility for a $1 million annual target bonus.
Despite Eli Lilly's drugs being approved by the US Food and Drug Administration (FDA), they still remain on the FDA's official drug shortage list and have spent most of their time on that list. This highlights the supply chain management and production capacity challenges in the weight loss drug industry. Currently, both Eli Lilly and Novo Nordisk are struggling to meet the enormous demand for their weight loss drugs. Eli Lilly has recently increased its production capacity and raised its annual sales forecast by $3 billion. In contrast, Novo Nordisk has fallen short of expectations in the most recent quarter.
Editor/Somer
